Document:

exv4w1

 

EXHIBIT 4.1

NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
(THE “SEC”) OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN
EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED FOR SALE, SOLD OR
OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
FILED UNDER THE SECURITIES ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION
UNDER SUCH ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR BLUE SKY
LAWS.

NEOTHERAPEUTICS, INC.

WARRANT

	Dated: July 8, 2002	Number
NEOT ________

     NeoTherapeutics, Inc., a Delaware corporation (the “Company”), hereby
certifies that, for value received, ________ or its registered assigns (“Holder”),
is entitled, subject to the terms set forth below, to purchase from the Company
up to a total of ________ shares of Common Stock, $.001 par value per share (the
“Common Stock”), of the Company (each such share, a “Warrant Share” and all
such shares, the “Warrant Shares”) at an exercise price equal to $0.30 per
share (as adjusted from time to time as provided in Section 7, the “Exercise
Price”), at any time and from time to time from and after the date hereof and
through and including July 8, 2007 (the “Expiration Date”), and subject to the
following terms and conditions:

     1. Registration of Warrant. The Company shall register this Warrant upon
records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The
Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, and the Company shall
not be affected by notice to the contrary.

     2. Registration of Transfers and Exchanges.

          (a) This Warrant or the Warrant Shares issued upon any exercise hereof may
only be transferred (i) pursuant to an effective registration statement under
the Securities Act, (ii) to the Company or (iii) pursuant to an available
exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act. In connection with any transfer of this
Warrant or any Warrant Shares other than pursuant to an effective registration
statement or to the Company, the Company may require the transferor thereof to
provide to the Company an opinion of counsel to the transferor, the form and
substance of which opinion shall be reasonably satisfactory to the Company, to
the effect that such transfer may be made without registration under the
Securities Act. Holder agrees to the imprinting, so long as is required by
applicable securities laws, of a legend substantially similar to that first
above written on any New Warrant

 

 

(as defined in Section 2(b) below) or certificates representing Warrant
Shares. Any such transferee shall agree by virtue of having a New Warrant
registered in its name in accordance with Section 2(b) below to be bound by the
terms of this Warrant and shall have the rights of Holder under this Warrant.

          (b) The Company shall register the transfer of any portion of this Warrant
in conformance with Section 2(a) in the Warrant Register, upon surrender of
this Warrant, with the Form of Assignment attached hereto duly completed and
signed, to the Company at the office specified in or pursuant to Section 10.
Upon any such registration or transfer, a new warrant to purchase Common Stock,
in substantially the form of this Warrant (any such new warrant, a “New
Warrant”), evidencing the portion of this Warrant so transferred shall be
issued to the transferee and a New Warrant evidencing the remaining portion of
this Warrant not so transferred, if any, shall be issued to the transferring
Holder. The acceptance of the New Warrant by the transferee thereof shall be
deemed the acceptance of such transferee of all of the rights and obligations
of a holder of this Warrant.

          (c) This Warrant is exchangeable, upon the surrender hereof by the Holder
to the office of the Company specified in or pursuant to Section 10 for one or
more New Warrants, evidencing in the aggregate the right to purchase the number
of Warrant Shares which may then be purchased hereunder.

     3. Duration and Exercise of Warrant.

          (a) This Warrant shall be exercisable by the then registered Holder on any
business day before 5:00 P.M., California time, at any time and from time to
time on or after the date hereof to and including the Expiration Date. At 5:00
P.M., California time on the Expiration Date, the portion of this Warrant not
exercised prior thereto shall be and become void and of no value.

          (b) Upon surrender of this Warrant, with the Form of Election to Purchase
attached hereto duly completed and signed, to the Company at its address for
notice set forth in Section 10 and upon payment of the Exercise Price
multiplied by the number of Warrant Shares that the Holder intends to purchase
hereunder, in the manner provided hereunder, all as specified by the Holder in
the Form of Election to Purchase, the Company shall promptly (and in any event,
within four business days) issue or cause to be issued and cause to be
delivered to or upon the written order of the Holder and in such name or names
as the Holder may designate, a certificate for the Warrant Shares issuable upon
such exercise, free of restrictive legends except as are required under
applicable securities laws. Any person so designated by the Holder to receive
Warrant Shares shall be deemed to have become holder of record of such Warrant
Shares as of the Date of Exercise of this Warrant.

          A “Date of Exercise” means the date on which the Company shall have
received (i) this Warrant (or any New Warrant, as applicable), with the Form of
Election to Purchase attached hereto (or attached to such New Warrant)
appropriately completed and duly signed, and (ii) payment of the Exercise Price
for the number of Warrant Shares so indicated by the holder hereof to be
purchased.

2

 

          (c) This Warrant shall be exercisable, either in its entirety or, from
time to time, for a portion of the number of Warrant Shares. If less than all
of the Warrant Shares which may be purchased under this Warrant are exercised
at any time, the Company shall issue or cause to be issued, at its expense, a
New Warrant evidencing the right to purchase the remaining number of Warrant
Shares for which no exercise has been evidenced by this Warrant.

          (d) Prior to the exercise of this Warrant, the Holder shall not be
entitled to any rights as a stockholder of the Company with respect to the
Warrant Shares, including (without limitation) the right to vote such shares,
receive dividends or other distributions thereon or be notified of stockholder
meetings (except as otherwise set forth in Section 7(f) herein).

     4. Payment of Taxes. The Company will pay any documentary stamp taxes
attributable to the issuance of Warrant Shares upon the exercise of this
Warrant; provided, however, that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the
registration of any certificates for Warrant Shares or Warrants in a name other
than that of the Holder. The Holder shall be responsible for all other tax
liability that may arise as a result of holding or transferring this Warrant or
receiving Warrant Shares upon exercise hereof.

     5. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or
destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution
for this Warrant, a New Warrant, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and indemnity,
if requested, satisfactory to it. Applicants for a New Warrant under such
circumstances shall also comply with such other reasonable regulations and
procedures and pay such other reasonable charges as the Company may prescribe.

     6. Reservation of Warrant Shares. The Company covenants that it will at
all times reserve and keep available out of the aggregate of its authorized but
unissued Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of this Warrant as herein provided, the number of Warrant
Shares which are then issuable and deliverable upon the exercise of this entire
Warrant, free from preemptive rights or any other actual contingent purchase
rights of persons other than the Holder. The Company covenants that all
Warrant Shares that shall be so issuable and deliverable shall, upon issuance
and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly authorized, validly issued and fully paid and nonassessable.

     7. Certain Adjustments. The Exercise Price and number of Warrant Shares
issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this Section 7. Upon each such adjustment of the Exercise
Price pursuant to this Section 7, the Holder shall thereafter prior to the
Expiration Date be entitled to purchase, at the Exercise Price resulting from
such adjustment, the number of Warrant Shares obtained by multiplying the
Exercise Price in effect immediately prior to such adjustment by the number of
Warrant Shares issuable upon exercise of this Warrant immediately prior to such
adjustment and dividing the product thereof by the Exercise Price resulting
from such adjustment.

3

 

          (a) If the Company, at any time while this Warrant is outstanding, (i)
shall pay a stock dividend (except scheduled dividends paid on outstanding
preferred stock which contain a stated dividend rate) or otherwise make a
distribution or distributions on shares of its Common Stock payable in shares
of Common Stock, (ii) subdivide outstanding shares of Common Stock into a
larger number of shares, or (iii) combine outstanding shares of Common Stock
into a smaller number of shares, the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock
(excluding treasury shares, if any) outstanding before such event and the
denominator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding after such event. Any adjustment made pursuant to
this Section shall become effective immediately after the record date for the
determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of
a subdivision or combination, and shall apply to successive subdivisions and
combinations.

          (b) In case of any reclassification of the Common Stock, any consolidation
or merger of the Company with or into another person, the sale or transfer of
all or substantially all of the assets of the Company or any compulsory share
exchange pursuant to which the Common Stock is converted into other securities,
cash or property, then the Holder shall have the right thereafter to exercise
this Warrant only into the shares of stock and other securities and property
receivable upon or deemed to be held by holders of Common Stock following such
reclassification, consolidation, merger, sale, transfer or share exchange, and
the Holder shall be entitled upon such event to receive such amount of
securities or property equal to the amount of Warrant Shares such Holder would
have been entitled to had such Holder exercised this Warrant immediately prior
to such reclassification, consolidation, merger, sale, transfer or share
exchange. The terms of any such consolidation, merger, sale, transfer or share
exchange shall include such terms so as to continue to give to the Holder the
right to receive the securities or property set forth in this Section 7(b) upon
any exercise following any such reclassification, consolidation, merger, sale,
transfer or share exchange.

          (c) If the Company, at any time while this Warrant is outstanding, shall
distribute to all holders of Common Stock (and not to holders of this Warrant)
evidences of its indebtedness or assets or rights or warrants to subscribe for
or purchase any security (excluding those referred to in Sections 7(a), and
(b)), other than as part of its dissolution or liquidation or the winding up of
its affairs, then in each such case the Exercise Price shall be determined by
multiplying the Exercise Price in effect immediately prior to the record date
fixed for determination of stockholders entitled to receive such distribution
by a fraction of which the denominator shall be the fair market value of a
share of Common Stock determined as of the record date mentioned above, and of
which the numerator shall be the fair market value of a share of Common Stock
determined as of such record date less the fair market value at such record
date of the portion of such assets or evidence of indebtedness so distributed
applicable to one outstanding share of Common Stock as determined by the
Company’s independent certified public accountants that regularly examines the
financial statements of the Company (an “Appraiser”).

4

 

          (d) For the purposes of this Section 7, the following clauses shall also
be applicable:

	       	(i)	  	Record Date. In case the Company
shall take a record of the holders of its Common Stock
for the purpose of entitling them (A) to receive a
dividend or other distribution payable in Common Stock
or in securities convertible or exchangeable into shares
of Common Stock, or (B) to subscribe for or purchase
Common Stock or securities convertible or exchangeable
into shares of Common Stock, then such record date shall
be deemed to be the date of the issue or sale of the
shares of Common Stock deemed to have been issued or
sold upon the declaration of such dividend or the making
of such other distribution or the date of the granting
of such right of subscription or purchase, as the case
may be.
	 
	       	(ii)	  	Treasury Shares. The number of
shares of Common Stock outstanding at any given time
shall not include shares owned or held by or for the
account of the Company, and the disposition of any such
shares shall be considered an issue or sale of Common
Stock.

          (e) All calculations under this Section 7 shall be made to the nearest
cent or the nearest 1/100th of a share, as the case may be.

          (f) If:

	       	(i)	  	the Company shall declare a dividend
(or any other distribution) on its Common Stock; or
	 
	       	(ii)	  	the Company shall declare a special
nonrecurring cash dividend on or a redemption of its
Common Stock; or
	 
	       	(iii)	  	the Company shall authorize the
granting to all holders of the Common Stock rights or
warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights; or
	 
	       	(iv)	  	the approval of any stockholders of
the Company shall be required in connection with any
reclassification of the Common Stock of the Company, any
consolidation or merger to which the Company is a party,
any sale or transfer of all or substantially all of the
assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other
securities, cash or property; or
	 
	       	(v)	  	the Company shall authorize the
voluntary dissolution, liquidation or winding up of the
affairs of the Company,

5

 

then the Company shall cause to be mailed to each Holder at their last
addresses as they shall appear upon the Warrant Register, at least 30 calendar
days prior to the applicable record or effective date hereinafter specified, a
notice stating (x) the date on which a record is to be taken for the purpose of
such dividend, distribution, redemption, rights or warrants, or if a record is
not to be taken, the date as of which the holders of Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of Common Stock of
record shall be entitled to exchange their shares of Common Stock for
securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer, share exchange, dissolution, liquidation
or winding up; provided, however, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice.

     8. Payment of Exercise Price. The Holder shall pay the Exercise Price in
immediately available funds by certified check or bank draft payable to the
order of the Company or by wire transfer to an account designated by the
Company.

     9. Fractional Shares. The Company shall not be required to issue or cause
to be issued fractional Warrant Shares on the exercise of this Warrant. The
number of full Warrant Shares which shall be issuable upon the exercise of this
Warrant shall be computed on the basis of the aggregate number of Warrant
Shares purchasable on exercise of this Warrant so presented. If any fraction
of a Warrant Share would, except for the provisions of this Section 9, be
issuable on the exercise of this Warrant, the Company shall pay an amount in
cash equal to the Exercise Price multiplied by such fraction.

     10. Notices. Any and all notices or other communications or deliveries
hereunder shall be in writing and shall be deemed given and effective on the
earliest of (i) the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile telephone number specified in this
Section prior to 5:00 p.m. (California time) on a business day, (ii) the
business day after the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile telephone number specified in this
Section later than 5:00 p.m. (California time) on any date and earlier than
11:59 p.m. (California time) on such date, (iii) the business day following the
date of mailing, if sent by nationally recognized overnight courier service, or
(iv) upon actual receipt by the party to whom such notice is required to be
given. The addresses for such communications shall be: (i) if to the Company,
to 157 Technology Drive, Irvine, CA 92618, Attention: Chief Financial Officer,
or to facsimile no. (949) 788-6706, or (ii) if to the Holder, to the Holder at
the address or facsimile number appearing on the Warrant Register or such other
address or facsimile number as the Holder may provide to the Company in
accordance with this Section 10.

     11. Warrant Agent. The Company shall serve as warrant agent under this
Warrant. The Company may appoint a new warrant agent upon notice to the Holder
in accordance with Section 10. Any corporation into which the Company may be
merged or any corporation resulting from any consolidation to which the Company
shall be a party or any corporation to which the Company transfers
substantially all of its corporate assets shall be a successor warrant agent
under this Warrant without any further act. Any such successor warrant agent
shall

6

 

 promptly cause notice of its succession as warrant agent to be mailed (by
first class mail, postage prepaid) to the Holder at the Holder’s last address
as shown on the Warrant Register.

     12. Miscellaneous.

          (a) This Warrant shall be binding on and inure to the benefit of the
parties hereto and their respective successors and permitted assigns. This
Warrant may be amended only in writing signed by the Company and the Holder and
their successors and assigns.

          (b) Subject to Section 12(a), above, nothing in this Warrant shall be
construed to give to any person or corporation other than the Company and the
Holder any legal or equitable right, remedy or cause under this Warrant. This
Warrant shall inure to the sole and exclusive benefit of the Company and the
Holder.

          (c) This Warrant shall be governed by and construed and enforced in
accordance with the internal laws of the State of California without regard to
the principles of conflicts of law thereof. The Company and the Holder hereby
irrevocably submit to the exclusive jurisdiction of the state and federal
courts sitting in Orange County, California, for the adjudication of any
dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, or that such
suit, action or proceeding is improper. Each of the Company and the Holder
hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by receiving a copy thereof
sent to it at the address in effect for notices to it under this instrument and
in the manner set forth in Section 10 above, and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process
in any manner permitted by law.

          (d) The headings herein are for convenience only, do not constitute a part
of this Warrant and shall not be deemed to limit or affect any of the
provisions hereof.

          (e) In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Warrant shall not in any way be affected
or impaired thereby and the parties will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable
substitute therefor, and upon so agreeing, shall incorporate such substitute
provision in this Warrant.

     13. Representations and Warranties of Holder. By accepting this Warrant,
the Holder hereby represents and warrants as follows:

          (a) Purchase for Own Account. Holder represents and warrants that it is
acquiring the Warrant and the Warrant Shares (collectively, the “Securities”)
solely for its own account for investment and not with a view to, or for resale
in connection with, any distribution thereof within the meaning of the
Securities Act. Holder further represents that it does not have any present
intention of selling, offering to sell or otherwise disposing of or
distributing the Securities or any portion thereof and that the entire legal
and beneficial interest of the Securities

7

 

it is acquiring is being acquired for, and will be held for the account
of, Holder only and neither in whole nor in part for any other person.

          (b) Accredited Investor; Informed and Knowledgeable Decision. Holder is
an accredited investor as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act. Holder hereby agrees, represents and warrants that
it is aware of the Company’s business affairs and financial condition and has
acquired sufficient information about the Company to reach an informed and
knowledgeable decision to acquire the Securities. Holder further represents
and warrants that it has discussed the Company and its plans, operations and
financial condition with its officers, has received all such information as he
deems necessary and appropriate to enable it to evaluate the financial risk
inherent in making an investment in the Securities.

          (c) Company Disclosure. Holder hereby agrees, represents and warrants
that the Company has disclosed to Holder that the Securities have not been
registered under the Securities Act or under any state securities laws and must
be held indefinitely unless a transfer of it is subsequently registered under
the Securities Act or an exemption from such registration is available.

          (d) Rule 144. The Holder hereby agrees, represents and warrants that the
Holder is aware of the provisions of Rule 144, promulgated under the Securities
Act.

8

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its authorized officer as of the date first indicated above.

	 	 	 
	 	NEOTHERAPEUTICS, INC.
	 
 
	 	By: 	/s/ Samuel Gulko
	 	

	 	Name: 	 Samuel Gulko
	 	

	 	Title: 	Sen. VP Finance, CFO, Sec & Treas.
	 	

9

 

FORM OF ELECTION TO PURCHASE

(To be executed by the Holder to exercise the right to purchase shares of
Common Stock under the foregoing Warrant)

To NeoTherapeutics, Inc.:

     In accordance with the Warrant enclosed with this Form of Election to
Purchase, the undersigned hereby irrevocably elects to purchase ________
shares of Common Stock (“Common Stock”), $.001 par value per share, of
NeoTherapeutics, Inc. encloses herewith $________ in cash, certified or
official bank check or checks, which sum represents the aggregate Exercise
Price (as defined in the Warrant) for the number of shares of Common Stock to
which this Form of Election to Purchase relates, together with any applicable
taxes payable by the undersigned pursuant to the Warrant.

     The undersigned requests that certificates for the shares of Common Stock
issuable upon this exercise be issued in the name of

	 	PLEASE INSERT SOCIAL SECURITY OR

TAX IDENTIFICATION NUMBER

 

(Please print name and address)

     If the number of shares of Common Stock issuable upon this exercise shall
not be all of the shares of Common Stock which the undersigned is entitled to
purchase in accordance with the enclosed Warrant, the undersigned requests that
a New Warrant (as defined in the Warrant) evidencing the right to purchase the
shares of Common Stock not issuable pursuant to the exercise evidenced hereby
be issued in the name of and delivered to:

(Please print name and address)

	 	 	 
	Dated:________, ___	
Name of Holder:
	 
	 	
(Print)	
 

	 	 	 
	 	
(By:)	
 

	 	 	 
	 	
(Name:)	
 

	 	 	 
	 	
(Title:)	
 

	 	(Signature must conform in all respects to
name of
holder as specified on the face of
the Warrant)

 

 

FORM OF ASSIGNMENT

[To be completed and signed only upon transfer of Warrant]

     FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto ________ the right represented by the Warrant enclosed with
this Form of Assignment to purchase ________ shares of Common Stock of
NeoTherapeutics, Inc. to which the Warrant relates and appoints
_____________ attorney to transfer said right on the books of
NeoTherapeutics, Inc. with full power of substitution in the premises.

Dated: ________, ___

	 	

	 	(Signature must conform in all respects to
name of holder as specified on the face of
the Warrant)

	 	

	 	Address of Transferee
	 
	 	

	 
	 	

In the presence of:

 
	
	 

 

 

Schedule I

	 	 	 	 	 	 	 	 	 
	Warrant Number	 	Purchaser	 	Warrant Shares
	
	 	
	 	

	065
	 	Brighton
Capital Ltd.	 	 	1,500	 
	066
	 	Atwood Capital
Ltd.	 	 	1,500exv10w1

 

EXHIBIT 10.1

STOCK PURCHASE AGREEMENT

     This agreement is dated July 8, 2002 between ________ (“Purchaser”), and
NeoTherapeutics, Inc. (“Company”), whereby the parties agree as follows:

     The Purchaser shall buy and the Company agrees to sell ________shares
(“Shares”) of the Company’s Common Stock at a price of $0.17 per share for the
total amount of ________. The Shares have been registered on a Form S-3, File No.
333-53108, which registration statement has been declared effective by the
Securities and Exchange Commission. The Shares are free of restrictive legends
and are free of any resale restrictions. The Company is delivering herewith a
prospectus supplement on Form 424 (b)(2) regarding the sale of the Shares prior
to funding.

     The Purchaser shall wire the purchase amount to the Company to the account
set forth below.

Company Wire Transfer Instructions:

	 	Chase Manhattan Bank

1 Chase Plaza

New York, NY 10004

ABA # 021 000 021

FBO Salomon Smith Barney

A/C # 066-198038

For Further Credit to:

Neotherapeutics, Inc.

A/C # 561-04051-19-103

     The Company shall cause its transfer agent to transmit the Shares
electronically to the Purchaser by crediting the account set forth below
through the Deposit Withdrawal Agent Commission system.

     Purchaser DWAC Instructions:

	 	

 

-1-

 

	 	AGREED AND ACCEPTED:

	 	 	 
	 	NeoTherapeutics, Inc.
	 
 
	 	By: 
	 	

	 	 	
Name:

Title:

	 	 	 
	 	PURCHASER:
	 
	 	

	 
 
	 	By: 
	 	

	 	 	
Name:

Title:

-2-

 

SCHEDULE 1

	 	 	 	 	 	 	 	 	 
	Purchaser	 	Shares	 	Purchase Price
	
	 	
	 	

	Alpha Capital A.G.
	 	 	2,941,177	 	 	$	500,000	 
	Stonestreet L.P.
	 	 	1,764,705	 	 	$	300,000	 
	Excalibur Limited Partnership
	 	 	882,353	 	 	$	150,000	 
	Cranshire Capital L.P.
	 	 	882,353	 	 	$	150,000	 

-3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]